JP2007505942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505942A5 JP2007505942A5 JP2006527948A JP2006527948A JP2007505942A5 JP 2007505942 A5 JP2007505942 A5 JP 2007505942A5 JP 2006527948 A JP2006527948 A JP 2006527948A JP 2006527948 A JP2006527948 A JP 2006527948A JP 2007505942 A5 JP2007505942 A5 JP 2007505942A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aminoalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Heterocycloalkyloxy Chemical group 0.000 claims description 65
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 125000002252 acyl group Chemical group 0.000 claims description 42
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 42
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 40
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 38
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 125000001188 haloalkyl group Chemical group 0.000 claims description 36
- 125000004442 acylamino group Chemical group 0.000 claims description 33
- 125000004104 aryloxy group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000001769 aryl amino group Chemical group 0.000 claims description 26
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 24
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 24
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 24
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 24
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 24
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 24
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 24
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 24
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 23
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 18
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 18
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 108010033040 Histones Proteins 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241000283707 Capra Species 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 claims 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 241000223105 Trypanosoma brucei Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50421403P | 2003-09-22 | 2003-09-22 | |
| US60/504,214 | 2003-09-22 | ||
| US53089003P | 2003-12-22 | 2003-12-22 | |
| US60/530,890 | 2003-12-22 | ||
| PCT/SG2004/000307 WO2005028447A1 (en) | 2003-09-22 | 2004-09-21 | Benzimidazole derivates: preparation and pharmaceutical applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505942A JP2007505942A (ja) | 2007-03-15 |
| JP2007505942A5 true JP2007505942A5 (enExample) | 2011-07-28 |
| JP5042626B2 JP5042626B2 (ja) | 2012-10-03 |
Family
ID=34381112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527948A Expired - Fee Related JP5042626B2 (ja) | 2003-09-22 | 2004-09-21 | ベンズイミダゾール誘導体：製造及び医薬適用 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US7781595B2 (enExample) |
| JP (1) | JP5042626B2 (enExample) |
| KR (1) | KR101127201B1 (enExample) |
| AR (1) | AR046411A1 (enExample) |
| AT (1) | ATE472534T1 (enExample) |
| BR (1) | BRPI0414581C1 (enExample) |
| CA (1) | CA2539766C (enExample) |
| DE (1) | DE602004027932D1 (enExample) |
| DK (1) | DK1673349T3 (enExample) |
| MY (1) | MY142589A (enExample) |
| NZ (1) | NZ545864A (enExample) |
| PT (1) | PT1673349E (enExample) |
| TW (1) | TWI349664B (enExample) |
| WO (1) | WO2005028447A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008108741A1 (en) * | 2007-03-07 | 2008-09-12 | S*Bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2003076401A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| CA2476583C (en) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| JP4648628B2 (ja) | 2002-03-13 | 2011-03-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体 |
| CN100396679C (zh) | 2002-03-13 | 2008-06-25 | 詹森药业有限公司 | 用作组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物 |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| HRP20120327T1 (hr) | 2004-07-28 | 2012-05-31 | Janssen Pharmaceutica Nv | Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze |
| ME01058B (me) | 2004-07-28 | 2012-10-20 | Janssen Pharmaceutica Nv | Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| DK1885710T3 (en) | 2005-05-18 | 2015-11-23 | Janssen Pharmaceutica Nv | SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006201177B2 (en) * | 2005-09-08 | 2012-06-14 | Mei Pharma, Inc. | Heterocyclic compounds |
| EP1937650B1 (en) * | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
| JP2007077085A (ja) * | 2005-09-15 | 2007-03-29 | Univ Of Tokyo | Ｈｄａｃ阻害活性を有する新規置換ヒドロキサム酸誘導体 |
| CA2623360C (en) | 2005-10-27 | 2014-04-22 | Janssen Pharmaceutica N.V. | Squaric acid derivatives as inhibitors of histone deacetylase |
| CN101374801B (zh) * | 2005-12-19 | 2014-07-02 | 梅特希尔基因公司 | 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂 |
| DK1981875T3 (da) | 2006-01-19 | 2014-07-14 | Janssen Pharmaceutica Nv | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase |
| ES2327972T3 (es) | 2006-01-19 | 2009-11-05 | Janssen Pharmaceutica, N.V. | Derivados de aminofenil como nuevos inhibidores de histona deacetilasa. |
| JP5225103B2 (ja) | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新規なインヒビターとしてのヘテロシクリルアルキル誘導体 |
| EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| EP1979327A1 (en) | 2006-01-19 | 2008-10-15 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US7888360B2 (en) | 2006-01-19 | 2011-02-15 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US8338416B2 (en) | 2006-03-16 | 2012-12-25 | Pharmacylics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| ATE478067T1 (de) * | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| AU2007235577B2 (en) * | 2006-03-31 | 2011-09-15 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor |
| EP2064211B1 (en) * | 2006-09-20 | 2015-11-11 | MEI Pharma, Inc. | Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| MX2009006327A (es) * | 2006-12-15 | 2009-06-23 | Novartis Ag | Compuestos heterociclicos y metodos de uso de los mismos. |
| JP2010513326A (ja) * | 2006-12-19 | 2010-04-30 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ |
| DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
| US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| US8987468B2 (en) * | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| EP2254572B1 (en) | 2008-02-07 | 2013-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh-1 expression |
| MX2010011168A (es) | 2008-04-15 | 2010-12-21 | Pharmacyclics Inc | Inhibidores selectivos de histona-desacetilasa. |
| US20110288070A1 (en) * | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| US20100212036A1 (en) * | 2008-09-30 | 2010-08-19 | Olson Eric N | Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| EP2305643A1 (en) | 2009-10-02 | 2011-04-06 | Ikerchem, S.L. | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| EP2493310A4 (en) * | 2009-10-27 | 2014-03-12 | Glaxosmithkline Llc | BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE |
| CN101881735B (zh) * | 2010-06-11 | 2011-11-16 | 赵永秀 | 尿液中百草枯的检测方法 |
| JP5782234B2 (ja) * | 2010-06-16 | 2015-09-24 | チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ | ベンゾイミダゾール化合物およびその使用 |
| EP2397471A1 (en) * | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| TW201245115A (en) | 2011-01-24 | 2012-11-16 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2013066832A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| TW201408628A (zh) | 2012-07-16 | 2014-03-01 | Chdi Foundation Inc | 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法 |
| CN103755595A (zh) * | 2012-12-25 | 2014-04-30 | 中南大学 | 异羟肟酸类衍生物及其应用 |
| JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
| WO2015054099A1 (en) | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| EP3060217B1 (en) | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| CN107108521A (zh) * | 2014-10-28 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的杂环衍生物 |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| US9745253B2 (en) | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
| EP3294715B1 (en) | 2015-05-11 | 2020-05-06 | Kancera AB | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| KR20170049279A (ko) * | 2015-10-28 | 2017-05-10 | 엘지전자 주식회사 | 이동 단말기 |
| CN108602812B (zh) * | 2015-12-22 | 2021-11-02 | 坎塞拉有限公司 | 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物 |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| TWI659949B (zh) * | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| WO2018219309A1 (zh) * | 2017-06-02 | 2018-12-06 | 沈阳化工研究院有限公司 | 一种芳乙烯衍生物及其应用 |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| US20230159468A1 (en) | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| WO2021251565A1 (en) * | 2020-06-12 | 2021-12-16 | Hk Inno.N Corporation | Pharmaceutical composition comprising benzimidazole derivative compound |
| CA3187867A1 (en) * | 2020-07-03 | 2022-01-06 | Nihon Nohyaku Co., Ltd. | Anticoccidial agent and method for using the same |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| KR102730905B1 (ko) * | 2022-05-03 | 2024-11-15 | 충북대학교 산학협력단 | 신규한 n-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CN115368239B (zh) * | 2022-09-01 | 2024-04-26 | 南开大学 | 一种肉桂酸酯衍生物的合成及其制药应用 |
| KR102541577B1 (ko) | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
| CN116440130B (zh) * | 2023-04-12 | 2025-07-25 | 西藏农牧学院 | 苯并噻唑化合物在制备抑制白色念珠菌产品中的应用 |
| IL324858A (en) * | 2023-05-30 | 2026-01-01 | 16380026 Canada Inc | Cyp26b1 inhibitor compounds and methods of use thereof |
| CN122277558A (zh) * | 2026-05-27 | 2026-06-26 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 2-苯基咪唑并[1,2-α]吡啶类化合物及制备方法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) * | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| ATE198601T1 (de) | 1992-05-20 | 2001-01-15 | Merck & Co Inc | Ester derivate von 4-aza-steroiden |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| ID30439A (id) * | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| US6329380B1 (en) * | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| IL147150A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| ATE250932T1 (de) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| KR20100035666A (ko) * | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| CZ20013424A3 (cs) * | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2008108741A1 (en) | 2007-03-07 | 2008-09-12 | S*Bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| WO2003077855A2 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SG2013013339A (en) * | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003087089A1 (en) * | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2005065681A1 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| EP1937650B1 (en) | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
| PT2914254T (pt) | 2012-10-30 | 2020-04-02 | Mei Pharma Inc | Terapias de combinação para tratar cancros quimiorresistentes |
-
2004
- 2004-09-21 KR KR20067005698A patent/KR101127201B1/ko not_active Expired - Fee Related
- 2004-09-21 WO PCT/SG2004/000307 patent/WO2005028447A1/en not_active Ceased
- 2004-09-21 AT AT04775628T patent/ATE472534T1/de active
- 2004-09-21 AR ARP040103390 patent/AR046411A1/es active IP Right Grant
- 2004-09-21 BR BRPI0414581A patent/BRPI0414581C1/pt not_active IP Right Cessation
- 2004-09-21 MY MYPI20043871 patent/MY142589A/en unknown
- 2004-09-21 JP JP2006527948A patent/JP5042626B2/ja not_active Expired - Fee Related
- 2004-09-21 NZ NZ545864A patent/NZ545864A/en not_active IP Right Cessation
- 2004-09-21 DE DE200460027932 patent/DE602004027932D1/de not_active Expired - Lifetime
- 2004-09-21 TW TW093128611A patent/TWI349664B/zh not_active IP Right Cessation
- 2004-09-21 US US10/572,958 patent/US7781595B2/en not_active Expired - Fee Related
- 2004-09-21 PT PT04775628T patent/PT1673349E/pt unknown
- 2004-09-21 DK DK04775628T patent/DK1673349T3/da active
- 2004-09-21 CA CA 2539766 patent/CA2539766C/en not_active Expired - Fee Related
-
2010
- 2010-06-14 US US12/814,964 patent/US8551988B2/en not_active Expired - Fee Related
-
2013
- 2013-09-03 US US14/016,990 patent/US9024029B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 US US14/627,418 patent/US9402829B2/en not_active Expired - Fee Related
-
2016
- 2016-06-10 US US15/178,742 patent/US9717713B2/en not_active Expired - Fee Related
-
2017
- 2017-06-02 US US15/612,670 patent/US10201527B2/en not_active Expired - Fee Related
-
2018
- 2018-12-14 US US16/221,186 patent/US10736881B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60220188T2 (de) | Hemmer des phosphattransports | |
| JP4685068B2 (ja) | 脈管形成阻害活性を有するアリール尿素 | |
| KR101559963B1 (ko) | Ａｔｐ-결합 카세트 수송자의 조절자 | |
| US9504683B2 (en) | Heteroaryl derivatives as CFTR modulators | |
| CA2699382C (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP4871257B2 (ja) | ２−フェニルプロピオン酸誘導体およびそれらを含有する医薬組成物 | |
| RU2007116150A (ru) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола | |
| JP2001523712A (ja) | Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 | |
| JP2009536969A (ja) | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物 | |
| KR20140090231A (ko) | Atp-결합 카세트 수송체의 조절제 | |
| ZA200205660B (en) | Corticotropin releasing factor antagonists. | |
| KR20230149861A (ko) | 아픽사반 제제 | |
| WO2000031021A1 (fr) | INHIBITEURS DE PRODUCTION/DE SECRETION DE PROTEINE β-AMYLOIDE | |
| US9969701B2 (en) | Salts and co-crystals of lesinurad | |
| JP2018509446A (ja) | Ｎ−（５−シアノ−４−（（２−メトキシエチル）アミノ）ピリジン−２−イル）−７−ホルミル−６−（（４−メチル−２−オキソピペラジン−１−イル）メチル）−３，４−ジヒドロ−１，８−ナフチリジン−１（２ｈ）−カルボキサミドの粒子 | |
| JP2006510728A5 (enExample) | ||
| ZA200602181B (en) | Benzimidazole derivatives: Preparation and pharmaceutical applications | |
| CN112135615B (zh) | 包含吲哚类化合物的肾病综合征治疗或预防剂 | |
| DE3884858T2 (de) | Phenol-thioalkylamide als Inhibitoren von 5-Lipoxygenase. | |
| JP2007535554A5 (enExample) | ||
| JP2009520018A5 (enExample) | ||
| US4940712A (en) | Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors | |
| CN110483425B (zh) | 一种酰基硫脲类化合物及其制备方法与抗甲型流感病毒的应用 | |
| WO2017216579A1 (en) | Autophagy inducer compounds | |
| US20040132743A1 (en) | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) |